keyword
MENU ▼
Read by QxMD icon Read
search

RA treatment

keyword
https://www.readbyqxmd.com/read/28811354/safety-and-efficacy-of-baricitinib-through-128-weeks-in-an-open-label-longterm-extension-study-in-patients-with-rheumatoid-arthritis
#1
Edward C Keystone, Mark C Genovese, Douglas E Schlichting, Inmaculada de la Torre, Scott D Beattie, Terence P Rooney, Peter C Taylor
OBJECTIVE: To assess the safety and efficacy of baricitinib in patients with rheumatoid arthritis (RA) up to 128 weeks in a phase IIb study (NCT01185353). METHODS: After a 24-week blinded period, eligible patients entered an initial 52-week open-label extension (OLE); patients receiving 8 mg once daily (QD) continued with that dose and all others received 4 mg QD. Doses could be escalated to 8 mg QD at 28 or 32 weeks at investigator discretion when ≥ 6 tender and ≥ 6 swollen joints were present...
August 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28811047/development-of-an-item-bank-to-measure-factual-disease-and-treatment-related-knowledge-of-rheumatoid-arthritis-patients-in-the-treat-to-target-era
#2
Marieke J de Jonge, Martijn A H Oude Voshaar, Anita M P Huis, Mart A F J van de Laar, Marlies E J L Hulscher, Piet L C M van Riel
OBJECTIVE: To develop a Disease and treatment associated Knowledge in RA item bank (DataK-RA) based on item response theory. METHODS: Initial items were developed from a systematic review. Rheumatology professionals identified relevant content trough a RAND modified Delphi scoring procedure and consensus meeting. RA patients provided additional content trough a focus group. Patients and professionals rated readability, feasibility and comprehensiveness of resulting items...
July 21, 2017: Patient Education and Counseling
https://www.readbyqxmd.com/read/28811043/treatment-of-the-fixation-surface-improves-glenoid-prosthesis-longevity-in-vitro
#3
Sarah Junaid, Sanjay Sanghavi, Carolyn Anglin, Anthony Bull, Roger Emery, Andrew A Amis, Ulrich Hansen
Many commercial cemented glenoid components claim superior fixation designs and increased survivability. However, both research and clinical studies have shown conflicting results and it is unclear whether these design variations do improve loosening rates. Part of the difficulty in investigating fixation failure is the inability to directly observe the fixation interface, a problem addressed in this study by using a novel experimental set-up. Cyclic loading-displacement tests were carried out on 60 custom-made glenoid prostheses implanted into a bone substitute...
July 22, 2017: Journal of Biomechanics
https://www.readbyqxmd.com/read/28810629/inhibition-of-microrna-34a-ameliorates-murine-collagen-induced-arthritis
#4
Qiujie Dang, Fan Yang, Hongwei Lei, Xin Liu, Minglu Yan, He Huang, Xuemei Fan, Yang Li
Rheumatoid arthritis (RA) is one of the most frequently occurring autoimmne diseases, with symptoms including synovium hyperplasia, immune disorder, cartilage damage and bone resorption. It has previously been demonstrated that microRNA-34a (miR-34a) may participate in cell apoptosis, immune activation and bone metabolism, therefore the present study investigated the effects of miR-34a on RA. Collagen-induced arthritic (CIA) mice were employed as a murine model of experimental arthritis, and it was demonstrated that the level of miR-34a in the spleens, lymph nodes and synovium was increased in the CIA mice compared with normal DBA/1j mice...
August 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28810523/reactive-oxygen-species-mediated-nf-%C3%AE%C2%BAb-p38-feedback-loop-implicated-in-proliferation-inhibition-of-hfls-ra-cells-induced-by-1-7-dihydroxy-3-4-dimethoxyxanthone
#5
Jian Zuo, De-Yu Dou, Hui-Fang Wang, Yan-Hong Zhu, Yan Li, Jia-Jie Luan
1,7-Dihydroxy-3,4-dimethoxyxanthone (XAN) is a bioactive compound isolated from Securidaca inappendiculata Hassk. and exerts the inhibitory effects on fibroblast-like synoviocytes by targeting NF-κB and p38. This study was designed to elucidate mechanisms underlying the divergent regulation on the two pathways in HFLS-RA cells by XAN. Expressions of hallmark proteins and transcription of GADD45α mRNA were determined by Western-blot and RT-qPCR methods, respectively. Fluorescence staining was employed to evaluate intracellular oxidative stress...
August 11, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28808949/practical-management-of-respiratory-comorbidities-in-patients-with-rheumatoid-arthritis
#6
REVIEW
James Bluett, Meghna Jani, Deborah P M Symmons
Lung disease is one of the most common causes of extra-articular morbidity and mortality in patients with rheumatoid arthritis (RA). Development of pulmonary manifestations may be due to the systemic disease itself; to serious respiratory adverse events such as pneumonitis and infections secondary to therapy; or to lifestyle habits such as smoking. Rheumatologists often need to make important treatment decisions and plan future care in RA patients with respiratory comorbidities, despite the absence of clear evidence or consensus...
August 14, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28807652/severity-indices-in-rheumatoid-arthritis-a-systematic-review
#7
Esther Toledano, M Jesús García de Yébenes, Isidoro González-Álvaro, Loreto Carmona
OBJECTIVE: To identify tools designed to evaluate the severity of patients with rheumatoid arthritis (RA) in order to use them in the investigation of prognostic markers in early arthritis. METHODS: We conducted a systematic review of studies that developed/validated an index for RA disease severity. They were analyzed using the COSMIN checklist to assess their methodological quality. In addition, all the variables included were evaluated for their clarity of definition, feasibility and probability of being present in each outcome during the first 2 years of the disease course...
August 11, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/28806246/response-assessment-of-223ra-treatment-should-a-fluorocholine-pet-ct-be-performed
#8
Ana María García Vicente, Ángel Soriano Castrejón, Ruth Alvarez Cabellos, Belén Sanchez Gil, Nicolás Mohedano Mohedano
We present 3 cases of patients with castration-resistant prostate cancer and bone metastases treated with Ra, belonging to our prospective and multicenter ChoPET-Rad study. All patients underwent clinical, hematological, and biochemical monitoring between each Ra administration. Initial and follow-up F-fluorocholine PET/CT and Tc-biphosphonate bone scintigraphy were performed previously and after the third Ra administration. Both techniques correctly established the response to treatment, in agreement to the biochemical response, although differences in the disease expression (concordant and discordant patterns) were found because of the different radiotracer biodistribution and molecular information derived from them...
August 12, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28805099/short-term-daily-teriparatide-in-patients-with-rheumatoid-arthritis
#9
Tetsuya Kaneko, Koichi Okamura, Yukio Yonemoto, Chisa Okura, Takahito Suto, Masahiro Tachibana, Yasuyuki Tamura, Makoto Inoue, Hirotaka Chikuda
OBJECTIVE: The aim of this study was to compare the efficacy of six-month teriparatide treatment followed by six-month bisphosphonate therapy with 12-month bisphosphonate monotherapy in Japanese rheumatoid arthritis (RA) patients who had not been previously treated for osteoporosis. METHODS: A total of 34 RA patients with osteoporosis were enrolled. Thirteen patients received six-month teriparatide prior to six-month minodronate therapy (PTH group), and 21 patients received 12-month minodronate therapy (BP group)...
August 14, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28803127/direct-antioxidant-properties-of-methotrexate-inhibition-of-malondialdehyde-acetaldehyde-protein-adduct-formation-and-superoxide-scavenging
#10
Matthew C Zimmerman, Dahn L Clemens, Michael J Duryee, Cleofes Sarmiento, Andrew Chiou, Carlos D Hunter, Jun Tian, Lynell W Klassen, James R O'Dell, Geoffrey M Thiele, Ted R Mikuls, Daniel R Anderson
Methotrexate (MTX) is an immunosuppressant commonly used for the treatment of autoimmune diseases. Recent observations have shown that patients treated with MTX also exhibit a reduced risk for the development of cardiovascular disease (CVD). Although MTX reduces systemic inflammation and tissue damage, the mechanisms by which MTX exerts these beneficial effects are not entirely known. We have previously demonstrated that protein adducts formed by the interaction of malondialdehyde (MDA) and acetaldehyde (AA), known as MAA-protein adducts, are present in diseased tissues of individuals with rheumatoid arthritis (RA) or CVD...
August 2, 2017: Redox Biology
https://www.readbyqxmd.com/read/28802150/mir-let-7a-regulates-anti-citrullinated-protein-antibody-induced-macrophage-activation-and-correlates-with-the-development-of-experimental-rheumatoid-arthritis
#11
Wei Zhu, Jianbo Yu, Shou Qiu, Haifeng Liu, Yan Wang, Xiaoyan Xu, Lili Shao, Lingling Zhu, Yan Jiao, Fan Liu, Xiaodong Zhu
Anti-citrullinated protein antibodies (ACPAs) are a key serological marker of rheumatoid arthritis (RA). To investigate whether miR-let7a downregulated ACPA-induced macrophage activation and arthritis, miR-let7a levels were assessed in the synovial fluid from patients with RA or osteoarthritis (OA). In addition, expression of the pro-inflammatory genes HMGA2, PI3K, and IRF5 was examined in ACPA-induced macrophages and a collagen antibody-induced mouse model of arthritis. As expected, miR-let7a expression in synovial fluid macrophages was substantially lower in patients with RA than in those with OA...
August 9, 2017: International Immunopharmacology
https://www.readbyqxmd.com/read/28800780/a-novel-scoring-system-based-on-common-laboratory-tests-predicts-the-efficacy-of-tnf-inhibitor-and-il-6-targeted-therapy-in-patients-with-rheumatoid-arthritis-a-retrospective-multicenter-observational-study
#12
Jin Nakagawa, Yoshinobu Koyama, Atsushi Kawakami, Yukitaka Ueki, Hiroshi Tsukamoto, Takahiko Horiuchi, Shuji Nagano, Ayumi Uchino, Toshiyuki Ota, Mitsuteru Akahoshi, Koichi Akashi
BACKGROUND: Currently, although several categories of biological disease-modifying antirheumatic drugs (bDMARDs) are available, there are few data informing selection of initial treatment for individual patients with rheumatoid arthritis (RA). Therefore, tumor necrosis factor inhibitor (TNF-i) and tocilizumab (TCZ) are treated as equivalent treatments in the recent disease management recommendations. We focused on two anticytokine therapies, TCZ and TNF-i, and aimed to develop a scoring system that predicts a better treatment for each RA patient before starting an IL-6 or a TNF-i...
August 11, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28799414/the-clinical-use-of-a-fixed-dose-combination-of-insulin-degludec-and-liraglutide-xultophy-100-3-6-for-the-treatment-of-type-2-diabetes
#13
Kira Harris, Kimberly Lovin Nealy
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of the fixed-dose combination of insulin degludec and the glucagon-like peptide-I receptor agonist (GLP-1 RA), liraglutide (IDegLira) in the treatment of type 2 diabetes mellitus (T2DM). DATA SOURCES: A PubMed and MEDLINE search (1966 to July 2017) of the keywords insulin degludec, liraglutide, and type 2 diabetes mellitus was conducted. References were reviewed to identify additional citations...
August 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28798489/periphyton-effects-on-bacterial-assemblages-and-harmful-cyanobacterial-blooms-in-a-eutrophic-freshwater-lake-a-mesocosm-study
#14
Yingshun Cui, Long Jin, So-Ra Ko, Seong-Jun Chun, Hyung-Seok Oh, Chang Soo Lee, Ankita Srivastava, Hee-Mock Oh, Chi-Yong Ahn
Periphyton comprises a broad range of autotrophic and heterotrophic organisms that grow on submerged surfaces in aquatic environments. To investigate the ecological roles of periphyton and their symbiotic bacterial assemblages related to the control of cyanobacterial blooms, mesocosm experiments were performed in a eutrophic lake that is usually infested with harmful cyanobacterial blooms. Our results showed that periphyton, together with their symbionts, reduced Chl-a concentrations (up to 94%), improved water clarity and effectively controlled cyanobacterial blooms in the treatment mesocosm...
August 10, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28798049/patient-reported-outcomes-from-a-phase-3-study-of-baricitinib-versus-placebo-or-adalimumab-in-rheumatoid-arthritis-secondary-analyses-from-the-ra-beam-study
#15
Edward C Keystone, Peter C Taylor, Yoshiya Tanaka, Carol Gaich, Amy M DeLozier, Anna Dudek, Jorge Velasco Zamora, Jose Arturo Covarrubias Cobos, Terence Rooney, Stephanie de Bono, Vipin Arora, Bruno Linetzky, Michael E Weinblatt
BACKGROUND: To assess the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX). METHODS: In this double-blind phase 3 study, patients were randomised 3:3:2 to placebo (n=488), baricitinib 4 mg once daily (n=487), or adalimumab 40 mg biweekly (n=330) with background MTX. PROs included the SF-36, EuroQol 5-D (EQ-5D) index scores and visual analogue scale, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient's Global Assessment of Disease Activity (PtGA), patient's assessment of pain and Work Productivity and Activity Impairment Questionnaire-Rheumatoid Arthritis (WPAI-RA), and measures collected in electronic patient daily diaries: duration and severity of morning joint stiffness (MJS), Worst Ttiredness and Worst Joint Pain...
August 10, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28794554/mucocutaneous-manifestations-in-patients-with-rheumatoid-arthritis-a-cross-sectional-study-from-eastern-india
#16
Sudip Kumar Ghosh, Debabrata Bandyopadhyay, Surajit Kumar Biswas, Ivoreen Darung
BACKGROUND: Cutaneous manifestations are fairly common in rheumatoid arthritis (RA) and they can help in early diagnosis, prompt treatment, and hence reduced morbidity from the disease. AIMS: The objective of the present study was to find out the different patterns of dermatoses in a group of patients with RA from Eastern India. METHODOLOGY: Consecutive patients fulfilling the American Rheumatism Association 1987 revised criteria for the classification of RA and who had different dermatoses were included in this cross-sectional study done over a period of 8 years in a tertiary care hospital in Eastern India...
July 2017: Indian Journal of Dermatology
https://www.readbyqxmd.com/read/28794515/the-complement-system-as-a-potential-therapeutic-target-in-rheumatic-disease
#17
REVIEW
Leendert A Trouw, Matthew C Pickering, Anna M Blom
Complement activation is associated with common rheumatic diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and systemic vasculitis. Evidence linking complement activation to these diseases includes the presence of complement deposition in affected tissues, decreased levels of complement proteins and high levels of complement activation fragments in the blood and/or synovial fluid of patients with these diseases, as well as data from experimental models. Eculizumab, a monoclonal antibody that inhibits the complement component C5, is now approved for the treatment of rare conditions involving complement hyperactivation, and the success of this therapy has renewed interest in understanding the utility of complement inhibition in rheumatological practice, particularly for SLE...
August 10, 2017: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/28794381/clinical-characteristics-of-rheumatoid-arthritis-patients-achieving-functional-remission-after-six-months-of-non-tumor-necrosis-factor-biological-disease-modifying-antirheumatic-drugs-dmards-treatment
#18
Yusuke Miwa, Mayu Saito, Hidekazu Furuya, Ryo Yanai, Yuzo Ikari, Tomoki Hayashi, Tsuyoshi Kasama, Yoichi Toyoshima, Katsunori Inagaki
Objectives We aimed to identify the factors that predict the likelihood of remission based on a health assessment questionnaire (HAQ) in rheumatoid arthritis (RA) patients who received non-tumor necrosis factor (TNF) biologics for six months before they commenced definitive treatment. Methods The subjects consisted of 97 RA patients treated with tocilizumab or abatacept for 6 months. The following characteristics were investigated: age, gender, body mass index, steroid and methotrexate dosage, serum matrix metalloproteinase-3 levels, simplified disease activity index (SDAI) score, HAQ score (for assessing the activities of daily living [ADL]) and the short form (SF)-36 score (for assessing the quality of life [QOL])...
August 10, 2017: Internal Medicine
https://www.readbyqxmd.com/read/28794078/long-term-efficacy-and-safety-in-patients-with-rheumatoid-arthritis-continuing-on-sb4-or-switching-from-reference-etanercept-to-sb4
#19
Paul Emery, Jiří Vencovský, Anna Sylwestrzak, Piotr Leszczyński, Wieslawa Porawska, Barbara Stasiuk, Joanna Hilt, Zdenka Mosterova, Soo Yeon Cheong, Jeehoon Ghil
OBJECTIVES: SB4 (Benepali, Brenzys) is a biosimilar of reference etanercept (ETN). In a randomised, double-blind, 52-week study, SB4 demonstrated comparable efficacy and safety to ETN in patients with rheumatoid arthritis (RA). The open-label extension period evaluated long-term efficacy, safety and immunogenicity when continuing SB4 versus switching from ETN to SB4. METHODS: In the randomised, double-blind phase, patients received weekly subcutaneous administration of 50 mg SB4 or ETN with background methotrexate for up to 52 weeks...
August 9, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28793911/igg-fc-galactosylation-predicts-response-to-methotrexate-in-early-rheumatoid-arthritis
#20
Susanna L Lundström, Aase H Hensvold, Dorothea Rutishauser, Lars Klareskog, A Jimmy Ytterberg, Roman A Zubarev, Anca I Catrina
BACKGROUND: Methotrexate (MTX) is the standard first-line therapy in rheumatoid arthritis (RA) with variable clinical efficacy that is difficult to predict. The glycosylation status of immunoglobulin G (IgG) is altered in RA and influenced by MTX treatment. We aimed to further investigate if IgG glycosylation in untreated early RA can predict therapeutic response to MTX. METHODS: We used a shotgun proteomic approach to screen for the Fc glycopeptides in the serum of 12 control subjects and 59 untreated patients with early RA prior to and following MTX initiation...
August 9, 2017: Arthritis Research & Therapy
keyword
keyword
91514
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"